Patents by Inventor William Robert Wilson

William Robert Wilson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160031877
    Abstract: The invention provides kinase inhibitors of Formula I: wherein either: (1) R1 is H, and (a) R2 is (3-chlorobenzyl)oxy- and R3 is chloro; (b) R2 and R3, together with the carbon atoms to which they are attached, form 1-(3-fluorobenzyl)-1H-pyrazole; (c) R2 is 2-pyridinylmethoxy and R3 is chloro; (d) R2 and R3 are both chloro; (e) R2 is chloro and R3 is bromo; (f) R2 and R3 are both bromo; (g) R2 is fluoro and R3 is ethynyl; (h) R2 is chloro and R3 is ethynyl; (i) R2 is bromo and R3 is ethynyl; (j) other than when R2 is in the 3-position in combination with R3 in the 4-position, R2 is bromo and R3 is fluoro; (k) R2 is 2-pyridinylmethoxy and R3 is fluoro; or (l) R2 is 2-pyridinylmethoxy and R3 is bromo; or (2) at least one of R1, R2 and R3 is selected from benzyloxy, 3-chlorobenzyloxy and 2-pyridinylmethoxy and when at least one of R1, R2 and R3 is not benzyloxy, 3-chlorobenzyloxy or 2-pyridinylmethoxy, each of the others is independently selected from H, halogen, and C2-C4 alkynyl, with the proviso that
    Type: Application
    Filed: June 30, 2015
    Publication date: February 4, 2016
    Inventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Guo-Liang Lu, Ho Huat Lee, Amir Ashoorzadeh, Robert Forbes Anderson, William Robert Wilson, William Alexander Denny, Huai-Ling Hsu, Andrej Maroz, Stephen Michael Frazer Jamieson, Alexandra Marie Mowday, Kendall Marie Carlin
  • Publication number: 20160002222
    Abstract: The invention provides novel prodrug compounds comprising a kinase inhibitor and a reductively-activated fragmenting aromatic nitroheterocycle or aromatic nitrocarbocycle trigger, where the compound carries a positive charge. In preferred embodiments, the compounds are of Formula I: where: X is any negatively charged counterion; R1 is a group of the formula —(CH2)nTr, where Tr is an aromatic nitroheterocyde or aromatic nitrocarbocycle and —(CH2)nTr acts as a reductively-activated fragmenting trigger; and n is an integer from 0 to 6; R2, R3 and R4 may each independently be selected from aliphatic or aromatic groups of a tertiary amine kinase inhibitor (R2)(R3)(R4)N, or two of R2, R3, and R4 may form an aliphatic or aromatic heterocyclic amine ring of a kinase inhibitor, or one of R2, R3, and R4 may be absent and two of R2, R3 and R4 form an aromatic heterocyclic amine ring of a kinase inhibitor. The compounds of the invention are useful in treating proliferative diseases such as cancer.
    Type: Application
    Filed: June 4, 2015
    Publication date: January 7, 2016
    Inventors: Jeffrey Bruce Smaill, ADAM VORN PATTERSON, MICHAEL PATRICK HAY, WILLIAM ALEXANDER DENNY, WILLIAM ROBERT WILSON, GUO-LIANG LU, ROBERT FORBES ANDERSON, HO HUAT LEE, AMIR ASHOORZADEH
  • Patent number: 9101632
    Abstract: The invention provides kinase inhibitors of Formula I: wherein either: (1) R1 is H, and (a) R2 is (3-chlorobenzyl)oxy-and R3 is chloro; (b) R2 and R3, together with the carbon atoms to which they are attached, form 1-(3-fluorobenzyl)-1H-pyrazole; (c) R2 is 2-pyridinylmethoxy and R3 is chloro; (d) R2 and R3 are both chloro; (e) R2 is chloro and R1 is bromo; (f) R2 and R3 are both bromo; (g) R2 is fluoro and R3 is ethynyl; (h) R2 is chloro and R3 is ethynyl; (i) R2 is bromo and R3 is ethynyl; (j) other than when R1 is in the 3-position in combination with R3, in the 4-position, R2 is bromo and R3 is fluoro; (k) R2 is 2-pyridinylmethoxy and R3 is fluoro; or (l) R2 is 2-pyridinylmethoxy and R1 is bromo; or (2) at least one of R1, R2 and R3 is selected from benzyloxy, 3-chlorobenzyloxy and 2-pyridinylmethoxy and when at least one of R1, R2 and R3 is not benzyloxy, 3-chlorobenzyloxy or 2-pyridinylmethoxy, each of the others is independently selected from H, halogen, and C2-C4 alkynyl, with the proviso that
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: August 11, 2015
    Assignee: AUCKLAND UNISERVICES LIMITED
    Inventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Guo-Liang Lu, Ho Huat Lee, Amir Ashoorzadeh, Robert Forbes Anderson, William Robert Wilson, William Alexander Denny, Huai-Ling Annie Hsu, Andrej Maroz, Stephen Michael Frazer Jamieson, Alexandra Marie Mowday, Kendall Marie Carlin
  • Patent number: 9073916
    Abstract: The invention provides novel prodrug compounds comprising a kinase inhibitor and a reductively-activated fragmenting aromatic nitroheterocycle or aromatic nitrocarbocycle trigger, where the compound carries a positive charge. In preferred embodiments, the compounds are of Formula I: where: X is any negatively charged counterion; R1 is a group of the formula —(CH2)nTr, where Tr is an aromatic nitroheterocycle or aromatic nitrocarbocycle and —(CH2)nTr acts as a reductively-activated fragmenting trigger; and n is an integer from 0 to 6; R2, R3 and R4 may each independently be selected from aliphatic or aromatic groups of a tertiary amine kinase inhibitor (R2)(R3)(R4)N, or two of R2, R3, and R4 may form an aliphatic or aromatic heterocyclic amine ring of a kinase inhibitor, or one of R2, R3 and R4 may be absent and two of R2, R3 and R4 form an aromatic heterocyclic amine ring of a kinase inhibitor. The compounds of the invention are useful in treating proliferative diseases such as cancer.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: July 7, 2015
    Assignee: AUCKLAND UNISERVICES LIMITED
    Inventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Michael Patrick Hay, William Alexander Denny, William Robert Wilson, Guo-Liang Lu, Robert Forbes Anderson, Ho Huat Lee, Amir Ashoorzadeh
  • Publication number: 20120202832
    Abstract: The invention provides kinase inhibitors of Formula I: wherein either: (1) R1 is H, and (a) R2 is (3-chlorobenzyl)oxy- and R3 is chloro; (b) R2 and R3, together with the carbon atoms to which they are attached, form 1-(3-fluorobenzyl)-1H-pyrazole; (c) R2 is 2-pyridinylmethoxy and R3 is chloro; (d) R2 and R3 are both chloro; (e) R2 is chloro and R1 is bromo; (f) R2 and R3 are both bromo; (g) R2 is fluoro and R3 is ethynyl; (h) R2 is chloro and R3 is ethynyl; (i) R2 is bromo and R3 is ethynyl; (j) other than when R1 is in the 3-position in combination with R3, in the 4-position, R2 is bromo and R3 is fluoro; (k) R2 is 2-pyridinylmethoxy and R3 is fluoro; or (l) R2 is 2-pyridinylmethoxy and R1 is bromo; or (2) at least one of R1, R2 and R3 is selected from benzyloxy, 3-chlorobenzyloxy and 2-pyridinylmethoxy and when at least one of R1, R2 and R3 is not benzyloxy, 3-chlorobenzyloxy or 2-pyridinylmethoxy, each of the others is independently selected from H, halogen, and C2-C4 alkynyl, with the proviso tha
    Type: Application
    Filed: September 2, 2010
    Publication date: August 9, 2012
    Applicant: Auckland Uniservices Limited
    Inventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Guo-Liang Lu, Ho Huat Lee, Amir Ashoorzadeh, Robert Forbes Anderson, William Robert Wilson, William Alexander Denny, Huai-Ling (Annie) Hsu, Andrej Maroz, Stephen Michael Frazer Jamieson, Alexandra Marie Mowday, Kendall Marie Carlin
  • Publication number: 20120077811
    Abstract: The invention provides novel prodrug compounds comprising a kinase inhibitor and a reductively-activated fragmenting aromatic nitroheterocycle or aromatic nitrocarbocycle trigger, where the compound carries a positive charge. In preferred embodiments, the compounds are of Formula I: where: X is any negatively charged counterion; R1 is a group of the formula —(CH2)nTr, where Tr is an aromatic nitroheterocycle or aromatic nitrocarbocycle and —(CH2)nTr acts as a reductively-activated fragmenting trigger; and n is an integer from 0 to 6; R2, R3 and R4 may each independently be selected from aliphatic or aromatic groups of a tertiary amine kinase inhibitor (R2)(R3)(R4)N, or two of R2, R3, and R4 may form an aliphatic or aromatic heterocyclic amine ring of a kinase inhibitor, or one of R2, R3 and R4 may be absent and two of R2, R3 and R4 form an aromatic heterocyclic amine ring of a kinase inhibitor. The compounds of the invention are useful in treating proliferative diseases such as cancer.
    Type: Application
    Filed: March 11, 2010
    Publication date: March 29, 2012
    Inventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Michael Patrick Hay, William Alexander Denny, William Robert Wilson, Guo-Liang Lu, Robert Forbes Anderson, Ho Huat Lee, Amir Ashoorzadeh
  • Patent number: 7989451
    Abstract: The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula I and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: August 2, 2011
    Assignee: Auckland Uniservices Limited
    Inventors: Michael Patrick Hay, Adrian Blaser, William Alexander Denny, Kevin Owen Hicks, Ho Huat Lee, Karin Pchalek, Frederik Bastiaan Pruijn, Bronwyn Gae Siim, William Robert Wilson, Shangjin Yang
  • Patent number: 7816521
    Abstract: The compound 3-ethyl-6-[3-(4-morpholinyl)propoxy]-1,2,4-benzotriazine 1,4-dioxide and pharmacologically acceptable salts thereof. A method of treating cancer in a subject is also described in which 3-ethyl-6-[3-(4-morpholinyl)propoxy]-1,2,4-benzotriazine 1,4-dioxide or a pharmacologically acceptable salt thereof is administered to tumor cells in a hypoxic environment. Also described is a method of radiosensitising in a subject tumor cells of solid tumors in hypoxic conditions by administering to the subject a pharmaceutical composition containing 3-ethyl-6-[3-(4-morpholinyl)propoxy]-1,2,4-benzotriazine 1,4-dioxide or a pharmacologically acceptable salt thereof in an amount sufficient to produce radiosensitivity in the tumor cells, and subjecting the tumor cells to radiation.
    Type: Grant
    Filed: March 1, 2005
    Date of Patent: October 19, 2010
    Assignee: Auckland Uniservices Limited
    Inventors: William Alexander Denny, Michael Patrick Hay, Kevin Owen Hicks, Frederik Pruijn, William Robert Wilson, Karin Pchalek
  • Patent number: 7776924
    Abstract: Nitroaniline-based unsymmetrical mustards of the general formula (I) are provided, together with methods of preparation and methods for their use as prodrugs for gene-dependent enzyme prodrug therapy (GDEPT) and cell ablation therapy in conjunction with nitroreductase enzymes as hypoxia selective cytotoxins and as anticancer agents.
    Type: Grant
    Filed: October 8, 2003
    Date of Patent: August 17, 2010
    Assignee: Auckland Uniservices Limited
    Inventors: William Alexander Denny, Graham J. Atwell, Shangjin Yang, William Robert Wilson, Adam Vorn Patterson
  • Patent number: 7718688
    Abstract: The present invention relates generally to nitro-1,2-dihydro-3H-benzo[e]indoles and related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.
    Type: Grant
    Filed: October 21, 2005
    Date of Patent: May 18, 2010
    Assignee: Auckland Uniservices Limited
    Inventors: William Alexander Denny, William Robert Wilson, Ralph James Stevenson, Moana Tercel, Graham John Atwell, Shangjin Yang, Adam Vorn Patterson, Frederik Bastlaan Pruijn
  • Publication number: 20100010094
    Abstract: The present invention relates to novel nitrophenyl mustard and nitrophenylaziridine alcohols, to their corresponding phosphates, to their use as targeted cytotoxic agents; as bioreductive drugs in hypoxic tumours, and to their use in cell ablation, including gene-directed enzyme-prodrug therapy (GDEPT) and antibody-directed enzyme-prodrug therapy (ADEPT), in conjunction with nitroreductase enzymes.
    Type: Application
    Filed: August 11, 2009
    Publication date: January 14, 2010
    Applicant: Auckland Uniservices Limited
    Inventors: William Alexander Denny, Graham John Atwell, Shangjin Yang, William Robert Wilson, Adam Vorn Patterson, Nuala Ann Helsby
  • Patent number: 7629332
    Abstract: The present invention relates to a novel nitrophenyl mustard and nitrophenylaziridine alcohols, to their corresponding phosphates, to their use as targeted cytotoxic agents; as bioreductive drugs in hypoxic tumors, and to their use in cell ablation, including gene-directed enzyme-prodrug therapy (GPEPT) and antibody-directed enzymeprodrug therapy (ADEPT), in conjunction with nitroreductase enzymes.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: December 8, 2009
    Assignee: Auckland Uniservices Limited
    Inventors: William Alexander Denny, Graham John Atwell, Shangjin Yang, William Robert Wilson, Adam Vorn Patterson, Nuala Ann Helsby
  • Publication number: 20090186886
    Abstract: The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula I and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.
    Type: Application
    Filed: March 31, 2006
    Publication date: July 23, 2009
    Applicant: Auckland Uniservices Limited
    Inventors: Michael Patrick Hay, Adrian Blaser, William Alexander Denny, Kevin Owen Hicks, Ho Huat Lee, Karin Pchalek, Frederik Bastiaan Pruijn, Bronwyn Gae Siim, William Robert Wilson, Shangjin Yang
  • Publication number: 20080119442
    Abstract: The present invention relates generally to nitro-1,2-dihydro-3H-benzo[e]indoles and related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.
    Type: Application
    Filed: October 21, 2005
    Publication date: May 22, 2008
    Inventors: William Alexander Denny, William Robert Wilson, Ralph James Stevenson, Moana Tercel, Graham John Atwell, Shangjin Yang, Adam Vorn Patterson, Frederik Bastlaan Pruijn
  • Publication number: 20080064665
    Abstract: The present invention relates to a method for the production of an anti-cancer effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of a compound of Formula (I) wherein X represents at any available ring position —CONH—, —SO2NH—, —O—, —CH2—, NHCO— or —NHSO2—; R represents a lower C1-6 alkyl optionally substituted with one or more groups including hydroxyl, amino and N-oxides therefrom or dialkylamino and N-oxides therefrom; Y represents at any available ring position —N-aziridinyl, —N(CH2CH2W)2 or —N(CH2CHMeW)2, where each W is independently selected from halogen or —OS02Me; Z represents at any available ring position —NO2, -halogen, —CN, —CF3, or —SO2Me; or a pharmaceutically acceptable salt or derivative thereof, before, after or simultaneously with an effective amount of docetaxel.
    Type: Application
    Filed: January 18, 2007
    Publication date: March 13, 2008
    Applicant: Auckland Uniservices Limited
    Inventors: Adam Vorn Patterson, William Robert Wilson
  • Patent number: 7064117
    Abstract: This invention relates to a class of heterocycles and their metal complexes, and is particularly concerned with the use of these compounds in the preparation of prodrugs or as prodrugs that may be activated under hypoxic conditions by enzymes or by therapeutic ionising radiation, in the treatment of cancer. The invention also relates to the use of these heterocycles and the corresponding metal complexes in the preparation of medicaments and to compositions including the heterocycles or their metal complexes and to methods for preparing these compounds.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: June 20, 2006
    Assignee: Auckland Uniservices Limited
    Inventors: William Alexander Denny, William Robert Wilson, David Charles Ware, Graham John Atwell, Jared Bruce Milbank, Ralph James Stevenson
  • Publication number: 20040192686
    Abstract: The present invention relates to a synergetistic composition comprising one or more benzoazine-mono-N-oxides, and one or more benzoazine 1,4 dioxides for use in cancer therapy.
    Type: Application
    Filed: January 30, 2004
    Publication date: September 30, 2004
    Applicant: Auckland Uniservices Limited
    Inventors: William Robert Wilson, Frederik Bastiaan Pruijn, Bronwyn Gae Siim, Michael Patrick Hay, William Alexander Denny, Swarnalatha Akuratiya Gamage
  • Publication number: 20040138195
    Abstract: This invention relates to a class of heterocycles and their metal complexes, and is particularly concerned with the use of these compounds in the preparation of prodrugs or as prodrugs that may be activated under hypoxic conditions by enzymes or by therapeutic ionising radiation, in the treatment of cancer. The invention also relates to the use of these heterocycles and the corresponding metal complexes in the preparation of medicaments and to compositions including the heterocycles or their metal complexes and to methods for preparing these compounds.
    Type: Application
    Filed: January 29, 2004
    Publication date: July 15, 2004
    Inventors: William Alexander Denny, William Robert Wilson, David Charles Ware, Graham John Atwell, Jared Bruce Milbank, Ralph James Stevenson
  • Publication number: 20030101675
    Abstract: A corner of a timber building frame (10) having spaced studs (11), top plates (12) and bottom plates (13). Bottom plates (13) are located in this case on an on-ground slab (14), noggings (15) retain the studs (11) in their proper spaced relation. To prevent the frames from moving in response to wind while the frame is under construction and also afterwards to resist movement in the event of earthquakes or high winds, bracing panels (16) comprise an elongated panel dimensioned for location between adjacent vertical studs (11) and between the top and bottom plates (12and (13), each panel has opposed ends (17 and 18) and opposed sides (19 and 20) and an intermediate portion between the sides shown generally at (21), the intermediate portion includes diamond shaped strengthening sections (22) displaced laterally out of the plane of the panel.
    Type: Application
    Filed: September 23, 2002
    Publication date: June 5, 2003
    Inventor: William Robert Wilson
  • Patent number: 6517836
    Abstract: A range of aziridin-1-yl nitrobenzamides are provided for use as prodrugs in conjunction with nitroreductase (NR) enzymes. The amides may have 1 or 2-substituents which may be bulky and polar. For example, 5-(aziridin-1-yl)-N-[2-(4-morpholino)ethyl]-2,4-dinitrobenzamide of Formula (A) was found to be highly active against all NR+ cell lines tested.
    Type: Grant
    Filed: March 6, 2001
    Date of Patent: February 11, 2003
    Assignee: Auckland Uniservices Limited
    Inventors: William Alexander Denny, Graham John Atwell, Brian Desmond Palmer, William Robert Wilson